AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (914.7 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Postbiotics: emerging bioactive agents in cancer therapy

Sihan Li1,*Fashun Li1,*Jiasheng Tu1Lei Jiang1 ( )Xiqun Jiang2 ( )
NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients and Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China
MOE Key Laboratory of High-Performance Polymer Materials and Technology, Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Postbiotics, considered the functional successors of live probiotics, retain most of probiotics’ structural and/or bioactive properties, and are key mediators of probiotic–environment interactions. Beyond influencing tumor proliferation, metastasis, and immune regulation, postbiotics can enhance the effectiveness of current anti-cancer treatments. Postbiotic-based cancer therapy represents an advanced evolution of bacterial treatment with improved safety and treatment potential. However, the field is limited by postbiotics’ imprecise definition and lack of standardized manufacturing methods, which together hinder their clinical application. Here, we establish a systematic classification of postbiotics based on their formation processes, focusing on the complex mechanisms underlying their activity in anti-tumor therapy, their therapeutic promise, and their current clinical use and challenges. Our aim is to guide future research, translation, and industrial development.

References

【1】
【1】
 
 
Cancer Biology & Medicine
Pages 470-479

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Li S, Li F, Tu J, et al. Postbiotics: emerging bioactive agents in cancer therapy. Cancer Biology & Medicine, 2026, 23(4): 470-479. https://doi.org/10.20892/j.issn.2095-3941.2025.0511

142

Views

1

Downloads

0

Crossref

1

Web of Science

2

Scopus

Received: 31 August 2025
Accepted: 12 January 2026
Published: 19 February 2026
©2026 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)